Efficacy and safety of foslevodopa/foscarbidopa subcutaneous infusion in patients with prior deep brain stimulation
Tove Henriksen(Bispebjerg Hospital), Victor S.C. Fung(The University of Sydney), Megha Shah(Emory University), Menno V. Huisman(Leiden University Medical Center), Lars Bergmann(Universitätsklinikum Knappschaftskrankenhaus Bochum), Sonny Dhanani(University of Ottawa), Juan Carlos Martínez‐Castrillo(Hospital Universitario Ramón y Cajal), Resmi Gupta(AbbVie (United States)), Elizabeth Peckham(Central Texas Neurology Consultants), Pavnit Kukreja(AbbVie (United States)), Jason Aldred(Inland Northwest Health Services)
Cited by 0
Related Papers
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Prevalence of and Factors Associated With Nurse Burnout in the US
|JAMA Network Open|2021|661
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
|Journal of Thrombosis and Haemostasis|2016|442
Naturally Occurring Off-Switches for CRISPR-Cas9
|Cell|2016|419
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
|Movement Disorders|2023|351